Evelo Biosciences, Inc. is discovering and developing therapies designed to engage immune cells in the small intestine to drive therapeutic immune effects throughout the body for the treatment of inflammatory diseases and cancers. The action of its therapies is based upon the observation that immune cells in the small intestine have a central role in governing the immune, metabolic and neurological systems throughout the body. The Company refers to this relationship as small intestinal axis, or SINTAX, which represents the connections of the small intestine to all organs and tissues. The Company’s monoclonal microbials are orally-delivered pharmaceutical compositions of naturally-occurring, specific single strains of microbes. Evelo currently has one product candidate in multiple clinical trials, EDP1815, for the treatment of inflammatory diseases and the treatment of hyperinflammation caused by SARs-CoV-2. Evelo also has two additional product candidates for the treatment of inflammatory diseases: EDP1867 and EDP2939, and one additional product candidate for the treatment of cancer: EDP1908.